Wildfire smoke exposure and early childhood respiratory health: a 1 study of prescription claims data 2

- Radhika Dhingra^{1,2*}, Corinna Keeler³, Brooke S. Staley³, Hanna V. Jardel^{3,4}, Cavin Ward-Caviness⁴,
- 3 4 5 6 Meghan E. Rebuli ^{5,6}, Yuzhi Xi ¹, Kristen Rappazzo ⁴, Michelle Hernandez ⁵, Anne Chelminski ⁴, Ilona Jaspers ^{5,6}, Ana G. Rappold ⁴
- 7
- 8 ¹ Department of Environmental Sciences and Engineering, Gillings School of Global Public Health,
- 9 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- 10 ² Brody School of Medicine, East Carolina University, Greenville, NC, USA
- ³ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at 11
- 12 Chapel Hill, Chapel Hill, NC, USA.
- 13 ⁴ United States Environmental Protection Agency, Center for Public Health and Environmental
- 14 Assessment, Research Triangle Park, NC, USA.
- ⁵ Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, 15
- 16 NC, USA.
- ⁶ Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel 17
- 18 Hill, Chapel Hill, NC, USA.
- 19
- 20 *Corresponding Author: Radhika Dhingra, PhD, Department of Environmental Science and
- 21 Engineering, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive,
- 22 C.B 7431, Chapel Hill, NC 27599. E-mail address: RDhingra@unc.edu
- 23
- 24 **Keywords:** wildfire, wildfire smoke, smoke exposure, prenatal, perinatal, childhood respiratory disease;
- 25 prescription claims
- 26
- 27

28 Abstract

29 Wildfire smoke is associated with short-term respiratory outcomes including asthma exacerbation in 30 children. As investigations into developmental wildfire smoke exposure on children's longer-term 31 respiratory health are sparse, we investigated associations between developmental WSE and first use of 32 respiratory medications. Prescription claims from IBM MarketScan Commercial Claims and Encounters 33 database were linked with wildfire smoke plume data from NASA satellites based on Metropolitan 34 Statistical Area (MSA). A retrospective cohort of live infants (2010-2016) born into MSAs in six western 35 states, having prescription insurance, and whose birthdate was estimable from claims data was 36 constructed (N=184,703); of these, gestational age was estimated for 113,154 infants. MSA, gestational 37 age, and birthdate were used to estimate average weekly smoke exposure days (*smoke-day*) for each 38 developmental period: three trimesters, and two sequential 12-week periods post-birth. Medications 39 treating respiratory tract inflammation were classified using active ingredient and mode of administration 40 into three categories: : 'upper respiratory', 'lower respiratory', 'systemic anti-inflammatory'. To evaluate 41 associations between wildfire smoke exposure and medication usage, Cox models associating smoke-days 42 with first observed prescription of each medication category were adjusted for infant sex, birth-season, 43 and birthyear with a random intercept for MSA. Smoke exposure during postnatal periods was associated 44 with earlier first use of upper respiratory medications (1-12 weeks: hazard ratio (HR)=1.094 per 1-day 45 increase in average weekly smoke-day, 95% CI: (1.005,1.191); 13-24 weeks: HR=1.108, 95% CI: 46 (1.016,1.209)); sex-specific HRs varied by post-birth exposure window. Protective associations were 47 observed during gestational windows for both lower respiratory and systemic anti-inflammatory 48 medications; it is possible that these associations may be a consequence of live-birth bias. These findings 49 suggest wildfire smoke exposure during early postnatal developmental periods impact subsequent early 50 life respiratory health.

51 Introduction

52 Over the past two decades, frequency and severity of wildfire events has increased, resulting in 53 greater land area being burned each decade (3.3 and 6.8 million average acres per year in 1990s and 54 2010s, respectively(1)) and substantial economic impact (\$347 billion in 2016) that is expected to grow as 55 wildfire frequency increases (2). Wildfire smoke is a complex chemical mixture of both gases and small 56 particles and a major contributor to particulate matter (PM), including the fine fraction of PM (PM_{2.5})(3) 57 which has been implicated in over 8.8 million premature deaths worldwide (4).

58 Particulate matter (PM) exposure during wildfires is associated with acute respiratory and other 59 outcomes in children (5); in addition, wildfire exposures may increase exacerbation-of-asthma events as 60 indicated by hospitalizations, emergency department visits, and outpatient visits (6). In adults, controlled 61 exposure studies of short-term exposures to woodsmoke have underscored the role of smoke exposure in 62 respiratory dysfunction, and provide evidence of both systemic and respiratory inflammation (7). In 63 studies of biomass – a primary fuel source for wildfires – burning and woodsmoke, exposure to these 64 pollutants was associated with asthma related symptoms including wheeze in children (8). Epidemiologic 65 studies (9–14) provide further evidence that wildfire, woodsmoke, and biomass smoke exposures are 66 associated with an increased risk of respiratory infection and reduced lung function in children (15,16) 67 and adults (17–19).

68 While the acute effects of wildfire or biomass burning exposure have been somewhat established, 69 there is little known about the effects of *in utero* or in early life wildfire particulate matter exposure on 70 longer term respiratory health outcomes. Lung development continues through gestation into the postnatal 71 period, a likely critical window of respiratory susceptibility to air pollution (20). Additionally, PM 72 exposure during gestation (e.g., 21,22) and early childhood (e.g., 23) is linked to sex-specific respiratory 73 health outcomes in humans (21). Additional evidence comes from recent studies of non-human primates 74 where exposure to wildfire smoke in the post-natal period resulted in sex-specific attenuation of host-75 defense mediators and impaired lung function in adolescence (24).

76	As similar respiratory effects may also be possible in humans, we consider the research question:
77	Does exposure to wildfire smoke during gestation or in the early postnatal period result in earlier first use
78	of anti-inflammatory respiratory medications in early childhood? By investigating the association of
79	smoke exposure during multiple developmental periods with first use of respiratory medication, we
80	identify critical windows of development where exposure to wildfire smoke may result in increased
81	respiratory vulnerability in the population of young children.
82	
83	
84	Methods
85	Population.
86	We constructed a retrospective cohort of infants from the IBM MarketScan® Commercial Claims and
87	Encounters Research Database (MarketScan) born into six western U.S. states. MarketScan is a
88	proprietary deidentified claims database, comprised of data from private U.Sbased insurance companies.
89	This private claims dataset includes hospitalizations, outpatient visits, services, and prescription claims
90	data.
91	Children born between January 1, 2010 and December 31, 2016, in metropolitan statistical areas
92	(MSAs) in California, Oregon, Washington, Idaho, Montana, or Nevada (Figure 1; Table S1) were
93	eligible. Utilizing a validated algorithm (25,26) and ICD-9 or ICD-10 codes, birthdates were estimated for
94	each live birth (Appendix 1, Supplementary Material). The MSA was the smallest geographic unit
95	available in MarketScan, and therefore the primary spatial unit for assessing wildfire smoke exposure.
96	Birthdate and MSA were required to estimate exposure to wildfire smoke for all observations.
97	Each child was required to have continuous enrollment with the insurer with at least 1 week of
98	prescription coverage starting at birth. For each child, follow-up begins after risk period; specifically,
99	follow-up begins at birth for prenatal exposures, and after the post-natal risk period for postnatal
100	exposures. For each outcome, the end of follow-up, measured in weeks, was either date of the outcome,
101	the end date of continuous enrollment, or December 31, 2018, whichever came first. This resulted in two

102 analytic cohorts: the full cohort with 182,387 liveborn children and a sub-cohort with 113,154 liveborn 103 children that also had estimates for gestational age (hereafter, GA sub-cohort). This study (IRB No:20-104 2817) was evaluated and approved by the Institutional Review Board at the University of North Carolina 105 at Chapel Hill.

- 106
- 107 Gestational age estimation.

108 Gestational age was used in the GA sub-cohort to estimate with greater precision the average 109 weekly number of smoke exposure days for the portion of each trimester completed. For example, if a 110 child had a GA of 34 weeks, T1 and T2 estimates would be calculated as described above, but T3 would be the average weekly smoke exposure from the 27th week to the end of the 34th week. 111 112 As the MarketScan dataset does not explicitly contain variables for gestational age (GA) at 113 delivery, infant records were linked, where possible, to the birthing parent to allow for GA determination. 114 To estimate GA at birth, we used an algorithm based on ICD-9 codes for the number of completed weeks 115 of gestation, as described in Appendix 2 (Supplementary Material) (Adapted from 27); these codes 116 were obtained either from the infants' or the birthing parents' records. Observations with GA were not 117 evenly distributed across time due to the shift from ICD-9 to ICD-10 codes in the fall of 2015. Due to 118 marked changes in GA coding between ICD-9 and ICD-10 codes, we chose to estimate GA based on 119 ICD-9 codes only as they were used for the majority of the study period. 120

121 Outcome: First use of prescription respiratory medication.

122 Three outcomes were considered: the first prescription use of (1) upper respiratory, (2) lower

123 respiratory, and (3) systemic anti-inflammatory medication. Classifications for each of the three outcomes

- 124 are briefly summarized in **Table S2**. As systemic anti-inflammatory medications are often used in acute
- 125 cases of inflammation or infection that could involve the lower respiratory tract, the upper respiratory
- 126 tract or other organ system, we chose to analyze them separately from medications used more specifically
- 127 for the upper or lower respiratory tract. If a child was prescribed medications from two outcome classes

128 on separate or the same claim date, they were assumed to have the event in analysis of both outcomes.

129 Medications were selected using a combination of *mode of administration (MSTFMDS* variable in

130 MarketScan), therapeutic drug classes (THERCLS), and therapeutic drug groups (THERGRP) as defined

131 in Micromedex RedBook (28) in consultation with a pediatric allergist, and referencing Up-To-Date (29);

132 final classification of medications were validated by two physicians. The outcome event was defined as

133 date of the first fill of prescription respiratory medication in drug claims data.

- 134
- 135 Exposure: Average weekly wildfire exposure smoke-days.

136 Wildfire smoke exposure data were obtained from the publicly available NASA satellite imagery-137 based Hazard Mapping System Fire and Smoke product (30,31) and were previously used to generate 138 smoke-day exposure estimates for each ZIP Code Tabulation Area (ZCTA) in the study area (10). These 139 data use visible plumes observed via satellite imaging as an approximation of true wildfire smoke 140 exposure. Using these data, we constructed MSA-level daily smoke-day exposures as follows: First, we 141 used the official crosswalk files released by the United States Office of Housing and Urban Development 142 to define membership within an MSA for each ZCTA in the study area, for each year of the study (32,33). 143 A MSA was defined as having a smoke-day on a given date if at least 25% of the population of the MSA 144 experienced a smoke-day, based on weighting the binary ZCTA smoke-days by year-specific ZCTA 145 population; we refer to this exposure measurement as the "25% threshold" smoke-day.

146 In sensitivity analyses, we further examined how estimated proportion of the MSA population 147 exposed in developing the exposure metric might impact observed associations. Because each MSA 148 contained a differing number of ZCTAs, we also defined two additional exposure measures for use in this 149 sensitivity analyses: (1) if any ZCTA within that MSA had a smoke-day on a given date, the MSA was 150 defined as having a smoke-day on that date [hereafter referred to as "0% threshold"]; and (3) if 50% of 151 the population of the MSA experienced a smoke-day on a given date, based on weighting the binary 152 ZCTA smoke-days by year-specific ZCTA population, the MSA was defined as having a smoke-day on 153 that date [50% threshold]. Thus, the "0% threshold" and "50% threshold" roughly correspond to average

weekly smoke-days experienced by greater than 0% or 50% of the MSA's population, respectively
(Figure 2). All analyses were conducted using each of these exposure thresholds, with the 25% threshold
smoke-day exposure utilized in the primary analyses, and the 0% and 50% thresholds applied in
sensitivity analyses.

Smoke-day exposures were linked to each liveborn child according to residential MSA at birth.
For each child, the number of smoke-days were summed in each exposure period and divided by the
number of weeks in the period to produce average weekly smoke-day estimates. This transformation
allows comparison across periods with differing durations and across individuals with various GAs.
Average weekly smoke-day estimates for each period were generated for each of the three exposure

163 thresholds.

In the full cohort, we estimated the average weekly wildfire smoke-days for the following time periods: each trimester of gestation, and two consecutive 12-week periods after birth. First, second, and third trimesters (T1, T2, & T3) were assumed to be 280-197, 196-99, & 98-1 days before the estimated date of birth, respectively. In the full cohort, postnatal exposure periods, P1 and P2, were defined 1-84 days (1-12 weeks) and 85-168 days (13-24 weeks) after birth, respectively.

In the GA sub-cohort, we additionally used GA to more accurately estimate the average weekly
smoke-days for the portion of each trimester completed (clarifying example in Supplementary
Material). To distinguish between exposures obtained under the assumption of 40-week gestation (full

172 cohort) and those obtained using estimated GA (GA sub-cohort), we use the suffix '-40w' or '-GA',

- 173 respectively.
- 174
- 175 Statistical Analyses.

For each trimester and postnatal period, mixed effects Cox proportional hazards models were used to estimate the hazard ratio (HR) for the association between the weekly average smoke-days and each prescription outcome. Follow-up time was counted in weeks. The association between average weekly smoke exposure and first use of medications was estimated using the function below:

1	80
---	----

181
$$\lambda_{ij}(t) = \lambda_o(t) \exp[\beta_1 Smoke_{ij} + \beta_2 Sex_{ij} + \beta_3 Birthyear_{ij} + \beta_4 Birth Season_{ij} + w_i MSA_i]$$
 (1)
182

where $\lambda_{ii}(t)$ is the probability of the first filled respiratory prescription at time t for child i in the ith MSA; 183 184 the MSA into which a child was born is the random intercept, and w_i is vector of coefficients for the 185 random intercept. Smoke is the average weekly number of smoke-days for the given trimester or postnatal 186 period. In addition to the two models of postnatal smoke-day exposures, separate models were estimated 187 for the six gestational smoke-day exposure periods (T1-40w, T2-40w, T3-40w, T1-GA, T2-GA, and T3-188 GA). A proxy for sex-specific hormones during development, sex was dichotomous (male/female). 189 Birthyear was included to adjust for time trends in both the propensity to prescribe medications and the 190 increasing number of smoke-days. Socioeconomic status was not available in the MarketScan database 191 within which all children were privately insured. The 4-category covariate Birth Season, defined as birth 192 during Spring (March-May), Summer (June-August), Fall (September-November), or Winter (December-193 February), was included to adjust for potential confounding. 194 Results for each trimester exposure are presented both for full cohort (all eligible births, assuming 195 a 40-week gestation) and for the GA sub-cohort (the subset of births with estimable gestational age). 196 Results for each postnatal exposure are presented for the full cohort only. Hazard ratios (HR (95% 197 confidence interval(CI))) are estimated for a one day increase in weekly average smoke-days. Results are 198 presented for all children as well as stratified on sex. 199 Though this analysis focuses on population-level effects rather than specific sub-populations or 200 etiologies (work-in-progress), we recognize that preterm birth (PTB) that may drive our main findings. As

201 such, we also stratified by PTB (defined as <37wks) within the GA-sub-cohort.

202

204 **RESULTS**

205	Across the study region of 60 MSAs in six western states (U.S.A.), each MSA had between 31
206	(Walla Walla, WA) and 24,860 (Los Angeles-Long Beach-Glendale, California) births recorded in
207	MarketScan during 2010-2016, with mean and median of 3,039 and 914 births per MSA, respectively
208	(Table S1). Los Angeles, Portland, and Seattle contributed the MSAs with the greatest number of births.
209	Of 182,387 eligible births with estimable birthdates (based on claims codes summarized in Appendix 1),
210	89,066 (48.8%) were female, and 113,154 (62.0%) also had an estimable GA (Table 1). The number of
211	births per year ranged from 18,578 to 32,721, and the sex distribution remained similar across years. In
212	the full cohort, Cetirizine hydrochloride (54.3%) and Mometasone furoate (34.8%) were the most
213	frequently filled upper respiratory prescriptions; Albuterol sulfate (90.0%) was the most frequently filled
214	lower respiratory prescription; Methylprednisolone, Prednisolone, or Prednisone (86.3%) was the most
215	frequently filled systemic anti-inflammatory prescriptions (Table S3).
216	On average, children were exposed to less than one day of smoke per week in each exposure
217	period; the mean trimester exposure ranged from 0.28 to 0.70 weekly smoke-days, and postnatal mean
218	exposure ranged from 0.37 to 0.74, across the thresholds (Table S4). Descriptive statistics for the full
219	cohort, the GA sub-cohort and those without GA were relatively comparable (Table S5).
220	
221	Postnatal period.
222	In both the first (P1) and second (P2) postnatal periods, the models reflected an association
223	between smoke-day exposure with earlier first use of upper respiratory medication (P1: HR=1.094 per 1-
224	day increase in weekly smoke-day (1.005, 1.191); P2: HR=1.108 (1.016, 1.209)); Figure 3, Table 2). In
225	the P1 period, female children had the larger effect size and stronger association (HR=1.123 (0.994,
226	1.27)) as compared to males (HR=1.055 (0.940, 1.185)). In contrast, male children had a larger effect size
227	(HR=1.128 (1.004, 1.266)) and stronger association in P2, as compared to female children (HR=1.072
228	(0.942, 1.22); Figure 3, Table 2). Associations in primary models (i.e., using the 25% threshold) of lower
229	respiratory as well as systemic anti-inflammatory outcomes were largely null (Figure 3, Table 2).

230

231 Gestational period

232 Positive associations with smoke exposure were observed only in the first trimester for the upper 233 respiratory outcome. The 40w- and GA- exposure models produced HRs in the same direction with 234 comparable magnitude, and with some variation in precision (Figure 3, Table 3). 235 Upper respiratory. In the primary model, the impact of smoke-days on the upper respiratory 236 medications outcome varied by gestational period, with increased risk in the first trimester, and null or 237 decreased risk in the second and third trimester (Figure 3, Table 3). In the first trimester, smoke-day 238 exposure was associated with shorter times to first upper respiratory medication, among all (HR=1.082 239 (0.985, 1.188)), and female children (HR=1.140 (0.997, 1.303)) among the full cohort (T1-40w), but not 240 in male children (HR=1.026 (0.902, 1.167); Figure 3); these first trimester HRs are comparable in the GA 241 sub-cohort (T1-GA), albeit with less precision in the 95% CI. For all other exposure windows, generally 242 null associations were consistently observed in both the full cohort and the GA sub-cohort. 243 *Lower respiratory.* Smoke-days had a null or slightly inverse association across all three 244 trimesters in the 40-week exposure modeled in both the full cohort and the GA sub-cohort (Figure 3, 245 **Table 3**). In contrast to first trimester upper respiratory outcome findings, first trimester smoke-day 246 exposure among the full cohort (T1-40w) was associated with delayed first lower respiratory medications 247 among all (HR=0.977 (0.951, 1.003)) and male children (HR=0.960 (0.927, 0.993)), but not in female 248 children (HR=0.997 (0.956, 1.039); Figure 3). 249 Systemic Anti-inflammatory. Second trimester smoke-day exposures in the GA sub-cohort (T2-

GA) were inversely associated with longer time to the use of systemic anti-inflammatory medication in all

- 251 (HR=0.946 (0.905, 0.989)) and male (HR=0.921 (0.869, 0.987)) children (**Figure 3**, **Table 3**). Similar,
- but smaller magnitude associations were observed in the first trimester (T1-GA) (All: HR=0.962 (0.927,
- 253 0.997); male: HR=0.959 (0.914, 1.006); Figure 3)). Interestingly, a similar protective association was
- found among female children in the third trimester (T3-GA) (HR=0.935 (0.892, 0.992)), but not among

255	male children. In the full cohort, the exposures across all trimesters and groups produce consistent and
256	similarly precise associations that are closer to the null than their counterparts in the GA sub-cohort.
257	
258	Sensitivity analyses
259	In the postnatal period, HRs and 95%CIs for both upper respiratory and systemic anti-
260	inflammatory outcomes are approximately similar across the 0%, 25% and 50% exposure thresholds
261	(Figure S1). For the lower respiratory outcome, however, results in the exposure sensitivity analyses are
262	more variable across thresholds.
263	For all trimester outcomes, the various thresholds used to generate smoke-day exposure estimates
264	generally had little effect on HR estimates, with some marginal changes in the confidence interval
265	precision (Figure S1). HR did not markedly differ between term births and PTBs.
266	
267	
268	DISCUSSION
269	Using private insurance claims data, we conducted a time-to-event analysis to estimate the
270	association between developmental exposure to wildfire smoke and first use of respiratory medication.
271	We found an association between smoke exposure during the first trimester, and both postnatal periods
272	with shorter time to first use of upper respiratory medication; these results were robust across exposure
273	definitions. This positive association between wildfire exposure and upper respiratory medication used
274	was larger for female children in the first trimester and the first 12-week postnatal period, while it was

stronger for male children in the 13-24 postnatal week period. These stratified results may suggest sex-

276 specific windows of vulnerability.

Additionally, for both systemic anti-inflammatory medication and lower respiratory medication,
protective effects of wildfire exposure were observed during most gestational windows. Most
prominently, we observed a shorter time to first lower respiratory medication use among male children
and all children during the first trimester; this finding was relatively consistent across cohort specification

(i.e., full cohort vs GA sub-cohort). Similarly, all children and male children had shorter times to first
systemic anti-inflammatory medication with increased smoke exposure during the first and second
trimesters; this was true also of girls in the first trimester. Whether the mechanism for these observed
protective effects is an artifact of observational epidemiology or a causal biological finding cannot be
ascertained in this dataset.

286 Our findings suggest a complex epidemiological relationship between gestational exposure to 287 wildfire smoke and time to first symptoms requiring respiratory prescription use. The juxtaposition of 288 below-null HRs during gestation with evidence in the literature suggesting that ambient air pollution is 289 not protective indicates that this analysis may suffer from selection bias (as do most perinatal 290 epidemiological studies (34)). In administrative datasets, these analyses are necessarily limited to live 291 births, and do not capture pregnancy loss. If the *in utero* response to wildfire smoke exposure is strong, 292 restricting the cohort to live births could lead to attrition of susceptible pregnancies and to an *in utero*-293 outcome association which is biased to appear less harmful or even protective. Indeed, non-human 294 primate work shows pregnancy loss is associated with wildfire smoke exposure (35).

295 The differing exposure pathways in the gestational and postnatal periods could also account for 296 the discrepancy in findings between these two developmental windows. Broadly, possible pathways for 297 air pollutants to exert influence on a fetus include altered placentation or placenta-mediated processes, 298 and direct fetal exposure. Recent work showed that PM can deposit in placental tissue and, to a lesser 299 extent, pass through the placenta to fetal capillaries (36–38). The increased tidal volume in the birthing 300 parent as well as the increased respiratory rate in young children may result in a larger dose of air 301 pollutants (39,40). Should this increased deposition of wildfire smoke pollutants in the birthing parent 302 impair placentation, there may be increased fetal loss as observed in non-human primates and mentioned 303 above (35). In the surviving fetuses, however, our inconsistent or null findings in the gestational period as 304 compared to positive upper respiratory postnatal findings, could indicate that direct exposure to nasal 305 epithelia, as occurs in the postnatal period, produces a more prominent and detectable increase in use of 306 respiratory medications.

307 Previous studies of PM exposures suggest specific respiratory conditions that could result from 308 wildfire smoke exposure, and may or may not require prescriptions treatment. For example, 309 developmental exposures to PM or biomass burning are associated with early life deficits in lung function 310 (41–43), and increased susceptibility to acute respiratory infection (ARI) or infant bronchiolitis (44,45). 311 While ARI is often treated with prescription medication in young children, subclinical deficits in lung 312 function associated with developmental air pollution exposure may not always be identified and treated 313 with prescription medication unless they lead to respiratory infection (21,43,46-51). It is possible that 314 study cohort members experienced respiratory symptoms that were transient, sub-clinical or well-315 managed with non-prescription medication, and thus were not captured in this analysis blunting any 316 potential association. 317 Because lung development occurs in phases starting in early gestation and continuing into 318 adolescence, damage in early life may have lasting negative effects. As PM is a component of wildfire 319 smoke exposure, the mechanisms by which such negative effects occur likely include a combination of 320 oxidative stress and inflammation, which may further induce physiological (52–54) or epigenetic changes 321 in the birthing parent and/or offspring (55,56). Early gestational exposure may lead to abnormal cellular 322 differentiation or branching due to a disruption of essential redox signaling (52), while later exposure may 323 induce structural or functional abnormalities (53,54). In non-human primates, early life exposure to 324 woodsmoke has been linked to reduced lung function metrics (24) which may be due to epigenetic 325 changes to respiratory tissues (57). 326 To our knowledge, this is the first analysis describing the impact of exposure to wildfire smoke

during development on prescription-treated respiratory conditions in human children. There are several additional strengths in this analysis. We were able to represent multiple exposure scenarios by using various thresholds for assigning smoke-days to an MSA. For example, because the definition of smokeday is based on the appearance of a plume from satellite data, adjacent areas may indeed be exposed to a lower level of smoke that, while not visible, is still impactful; this scenario is captured by the 0% threshold. We also explored refining exposure estimate using GA. Despite losing 38% of the dataset by

333 including claims-based estimates of GA, exaggerated effect estimates observed in the GA sub-cohort 334 suggest that accounting for GA captures important aspects of exposure relative to fetal development that 335 the assumption of 40-week gestation does not. The use of prescription claims data more accurately 336 captures medication usage than diagnosis or prescription delivery captured in electronic medical records. 337 Further the thorough categorization of these medications by two physicians ensures that they are 338 meaningfully classified. Finally, we were the first to leverage two widely used datasets to answer our 339 research question: well-vetted wildfire exposure data and private claims data able to capture prescription 340 usage.

341 First use of respiratory prescription medication as described in a private insurance claims 342 database serves as an indicator of respiratory health and vulnerability; this approach is not without 343 limitations. The MarketScan Commercial Claims and Encounters database is limited by omission of those 344 who are not on private insurance and those living in rural areas; this could make our results less 345 generalizable to other groups because of socioeconomic factors. While the Marketscan claims database 346 allows the examination of a large population distributed over a large wildfire-impacted region, the 347 availability of individual-level confounders, such as race, SES, and maternal or second-hand smoking, is 348 unfortunately limited. As observed with other air pollutant exposures (58), SES could modify the effect of 349 smoke exposure on respiratory health. Relatedly, this analysis assumes that all participants are exposed to 350 the same proportion of outdoor air pollution (e.g., that they spend the same amount of time outside and all 351 have the same/no indoor air purification systems), which may contribute to the potential for exposure bias 352 differential on SES or other related factors.

Imprecision in the estimates of residence may lead to exposure misclassification, though this impact is expected to be small given the size of a MSA in which exposures are defined as uniform due to the spatial coarseness of the data. MSA at birth provides a relatively coarse estimate of exposure which could be improved upon by using a dataset which includes more granular residential information. We also assumed that the MSA at time of birth was the same during the entirety of gestation; while likely not universally true, the impact of this assumption is expected to be small with potential bias toward the null

359 (59,60). Additionally, the coarseness of gestational age available in the ICD-9 coding system, wherein 360 codes are available at 2-week intervals between 24-37 weeks (inclusive), somewhat limits the accuracy of 361 our exposure estimates in the GA sub-cohort; such exposure misclassification may also induce bias in the 362 effect estimates. Finally, some respiratory outcomes may be lost by claims data, as it is only able to 363 provide information on conditions treated by prescription for those who have access to necessary care. 364 The modest differences in associations by sex found in this analysis contribute to growing 365 evidence supporting sex-differential effects of wildfire smoke exposure. There are well-documented sex 366 differences in lung development and asthma (61), including stress-induced oxidative response among 367 fetuses (62). Noted sex-specific reductions in lung function in non-human primates following wildfire 368 smoke exposure during infancy (24) may be exacerbated by prenatal PM exposure (21). 369 Overall, these findings suggest that first trimester and postnatal wildfire smoke exposure is 370 associated with shorter time to the first upper respiratory medication usage, while gestational wildfire 371 smoke exposure across trimesters is associated with longer time to systemic anti-inflammatory respiratory 372 prescription usage. This research supports the growing body of literature indicating that wildfire smoke 373 exposure in early life poses a health risk for pediatric populations, and adds granularity to the current 374 understanding of sex-specific and trimester-specific effects of in utero wildfire smoke exposure. 375 Clinicians may consider discussing the potential benefits of reducing exposure using evidenced-based 376 measures such as observing air quality index alerts, placing air purifiers in their home, and wearing face 377 masks to reduce particulate exposures. Future work should investigate specific clinical outcomes, such as 378 acute respiratory infection, and utilize finer spatial and temporal granularity to refine estimates of wildfire 379 smoke exposure. This work also highlights the continued need to evaluate measures to protect against 380 wildfire smoke during key developmental stages. 381

382 Declarations:

Authors contributions: RD, MER, and IJ conceived of the study question. AGR, CWC, and IJ obtained
 study funding. RD, CK, YX, and BSS built the dataset and carried out statistical analyses. KR, AGR, and

385 CW-C advised on statistical analyses and cohort development from claims data. RD classified

- medications as to the outcome and AC and MH reviewed these classifications. RD, CK, and HVJ draftedthe manuscript.
- 388 **Consent for publication** All authors revised the manuscript critically for intellectual content, gave final
- approval of the version to be published, and agreed to be accountable for all aspects of the work.
- 390 **Competing interests:** The authors declare they have no competing interests to disclose.
- **Funding:** Supported by the Environmental Protection Agency (EPA) Cooperative Agreement (U.S. EPA
- 392 CR83578501); HVJ was supported in part by an appointment to the ORISE participant research program
- 393 supported by an interagency agreement between EPA and DOE. CK was supported in part by a training
- 394 grant from the National Institute of Environmental Health Sciences [T32ES007018]. BSS was supported
- by the Genetic Epidemiology of Heart, Lung, and Blood Traits Training Grant [T32HL129982].
- **Disclaimer:** The views expressed in this article are those of the authors and do not necessarily represent
- 397 the views or policies of the U.S. Environmental Protection Agency.
- 398 Availability of data and materials: IBM MarketScan® Research Databases, a proprietary claims
- dataset, on which these analyses are based are available through IBM
- 400 (https://www.ibm.com/products/marketscan-research-databases). The environmental data from the
- 401 NOAA Hazards Mapping System that support the conclusions of this article are available in the U.S. EPA
- 402 Environmental Dataset Gateway (<u>https://www.ospo.noaa.gov/Products/land/hms.html maps).</u>
- 403 Ethics approval: This study (IRB No:20-2817) was evaluated and approved by the Institutional Review
- 404 Board at the University of North Carolina at Chapel Hill.
- 405 Acknowledgements: The authors would like to acknowledge Michele Jonnson-Funk, Virginia Pate, and
- 406 Tom Luben for their support and guidance in this developing this work.
- 407
- 408 Abbreviations:
- 409 WSE: Wildfire smoke exposure

- 410 MSA: Metropolitan Statistical Area
- 411 PM: Particulate matter
- 412 PM_{2.5}: fine fraction of particulate matter
- 413 MarketScan: IBM MarketScan® Commercial Claims and Encounters Research Database
- 414 ICD: International Classification of Disease
- 415 ZCTA: ZIP Code Tabulation Area
- 416 MSTFMDS: mode of administration
- 417 THERCLS : therapeutic drug classes
- 418 THERGRP : therapeutic drug groups
- 419
- 420 GA: Gestational Age
- 421 T1, T2, T3: 1st, 2nd and 3rd trimesters, respectively
- 422 P1 and P2: 1st and 2nd consecutive 12-week postnatal period, respectively
- 423 HR: hazard ratio
- 424 95% CI: 95% confidence interval
- 425 PTB: pre-term birth

426 **References**:

- National Interagency Fire Center. Total Wildland Fires and Acres (1983-2021) [Internet].
 [cited 2022 Mar 24]. (Statistics). Available from: https://www.nifc.gov/fireinformation/statistics/wildfires
- 430 2. Fann N, Alman B, Broome RA, Morgan GG, Johnston FH, Pouliot G, et al. The health
 431 impacts and economic value of wildland fire episodes in the U.S.: 2008–2012. Sci Total
 432 Environ. 2018 Jan 1;610–611:802–9.
- 433
 433 3. Liu JC, Peng RD. The impact of wildfire smoke on compositions of fine particulate matter
 434 by ecoregion in the Western US. J Expo Sci Environ Epidemiol. 2019 Nov;29(6):765–76.
- 4. Lelieveld J, Pozzer A, Pöschl U, Fnais M, Haines A, Münzel T. Loss of life expectancy from
 air pollution compared to other risk factors: a worldwide perspective. Cardiovasc Res. 2020
 437 Sep 1;116(11):1910–7.
- Künzli N, Avol E, Wu J, Gauderman WJ, Rappaport E, Millstein J, et al. Health effects of
 the 2003 Southern California wildfires on children. Am J Respir Crit Care Med. 2006 Dec
 1;174(11):1221–8.
- 441 6. Reid CE, Maestas MM. Wildfire smoke exposure under climate change: impact on
 442 respiratory health of affected communities. Curr Opin Pulm Med. 2019 Mar;25(2):179–87.
- Rebuli ME, Speen AM, Martin EM, Addo KA, Pawlak EA, Glista-Baker E, et al. Wood
 Smoke Exposure Alters Human Inflammatory Responses to Viral Infection in a Sex-Specific
 Manner. A Randomized, Placebo-controlled Study. Am J Respir Crit Care Med. 2019 Apr
 15;199(8):996–1007.
- 8. Sigsgaard T, Forsberg B, Annesi-Maesano I, Blomberg A, Bølling A, Boman C, et al. Health
 impacts of anthropogenic biomass burning in the developed world. Eur Respir J. 2015
 Dec;46(6):1577–88.
- 450 9. DeFlorio-Barker S, Crooks J, Reyes J, Rappold AG. Cardiopulmonary Effects of Fine
 451 Particulate Matter Exposure among Older Adults, during Wildfire and Non-Wildfire Periods,
 452 in the United States 2008-2010. Environ Health Perspect. 2019 Mar;127(3):37006.
- 453 10. Wettstein ZS, Hoshiko S, Fahimi J, Harrison RJ, Cascio WE, Rappold AG. Cardiovascular
 454 and Cerebrovascular Emergency Department Visits Associated With Wildfire Smoke
 455 Exposure in California in 2015. J Am Heart Assoc. 2018;7(8):e007492.
- 456 11. Rappold AG, Stone SL, Cascio WE, Neas LM, Kilaru VJ, Carraway MS, et al. Peat bog
 457 wildfire smoke exposure in rural North Carolina is associated with cardiopulmonary
 458 emergency department visits assessed through syndromic surveillance. Environ Health
 459 Perspect. 2011 Oct;119(10):1415–20.
- 460 12. Haikerwal A, Akram M, Del Monaco A, Smith K, Sim MR, Meyer M, et al. Impact of Fine
 461 Particulate Matter (PM2.5) Exposure During Wildfires on Cardiovascular Health Outcomes.
 462 J Am Heart Assoc. 2015 Jul 15;4(7):e001653.

463 13. Morgan G, Sheppeard V, Khalaj B, Ayyar A, Lincoln D, Jalaludin B, et al. Effects of
464 bushfire smoke on daily mortality and hospital admissions in Sydney, Australia. Epidemiol
465 Camb Mass. 2010 Jan;21(1):47–55.

- 466 14. Delfino RJ, Brummel S, Wu J, Stern H, Ostro B, Lipsett M, et al. The relationship of
 467 respiratory and cardiovascular hospital admissions to the southern California wildfires of
 468 2003. Occup Environ Med. 2009 Mar;66(3):189–97.
- 469 15. Mishra V. Indoor air pollution from biomass combustion and acute respiratory illness in
 470 preschool age children in Zimbabwe. Int J Epidemiol. 2003 Oct 1;32(5):847–53.
- 471 16. Oloyede IP, Ekrikpo UE, Ekanem EE. Lung Function Indices of Children Exposed to Wood
 472 Smoke in a Fishing Port in South-South Nigeria. J Trop Pediatr. 2013 Oct 1;59(5):399–402.
- 473 17. Fullerton DG, Suseno A, Semple S, Kalambo F, Malamba R, White S, et al. Wood smoke
 474 exposure, poverty and impaired lung function in Malawian adults. Int J Tuberc Lung Dis.
 475 2011 Mar 1;15(3):391–8.
- 476 18. García-Sancho MC, García-García L, Báez-Saldaña R, Ponce-de-León A, Sifuentes-Osornio
 477 J, Bobadilla-del-Valle M, et al. Indoor pollution as an occupational risk factor for
 478 tuberculosis among women: a population-based, gender oriented, case-control study in
 479 Southern Mexico. :8.
- 480 19. Pérez-Padilla R, Pérez-Guzmán C, Báez-Saldaña R, Torres-Cruz A. Cooking with biomass
 481 stoves and tuberculosis: a case control study. Int J Tuberc Lung Dis Off J Int Union Tuberc
 482 Lung Dis. 2001 May;5(5):441–7.
- 483 20. Wright RJ, Brunst KJ. Programming of respiratory health in childhood: influence of outdoor air pollution. Curr Opin Pediatr. 2013 Apr;25(2):232–9.
- 485 21. Hsu HL, Chiu YM, Coull BA, Schwartz J, Lee A, Wright RO, et al. Prenatal Particulate Air
 486 Pollution and Asthma Onset in Urban Children. Identifying Sensitive Windows and Sex
 487 Differences. Am J Respir Crit Care Med. 2015 Nov;192(9):1052–9.
- 488 22. Stapleton A, Casas M, García J, García R, Sunyer J, Guerra S, et al. Associations between
 489 pre- and postnatal exposure to air pollution and lung health in children and assessment of
 490 CC16 as a potential mediator. Environ Res. 2022 Mar 1;204:111900.
- 491 23. Schultz ES, Hallberg J, Bellander T, Bergström A, Bottai M, Chiesa F, et al. Early-Life
 492 Exposure to Traffic-related Air Pollution and Lung Function in Adolescence. Am J Respir
 493 Crit Care Med. 2016 Jan 15;193(2):171–7.
- 494 24. Black C, Gerriets JE, Fontaine JH, Harper RW, Kenyon NJ, Tablin F, et al. Early Life
 495 Wildfire Smoke Exposure Is Associated with Immune Dysregulation and Lung Function
 496 Decrements in Adolescence. Am J Respir Cell Mol Biol. 2017 May 1;56(5):657–66.

- 497 25. Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial
 498 hypertension in the USA: an epidemiological study in a large insured pediatric population.
 499 Pulm Circ. 2017 Mar;7(1):126–36.
- 500 26. Li Q, Andrade SE, Cooper WO, Davis RL, Dublin S, Hammad TA, et al. Validation of an
 501 algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiol
 502 Drug Saf. 2013 May;22(5):524–32.
- 503 27. Butler AM, Layton JB, Li D, Hudgens MG, Boggess KA, McGrath LJ, et al. Predictors of
 504 Low Uptake of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular
 505 Pertussis Immunization in Privately Insured Women in the United States. Obstet Gynecol.
 506 2017 Apr;129(4):629–37.
- 507 28. Truven Health Analytics/IBM Watson Health. IBM Micromedex RedBook [Internet]. 2021.
 508 Available from: https://www.micromedexsolutions.com
- 509 29. Up To Date. Up To Date. 2021.
- 30. Rolph GD, Draxler RR, Stein AF, Taylor A, Ruminski MG, Kondragunta S, et al.
 Description and Verification of the NOAA Smoke Forecasting System: The 2007 Fire
 Season. Weather Forecast. 2009 Apr 1;24(2):361–78.
- 513 31. Schroeder W, Ruminski M, Csiszar I, Giglio L, Prins E, Schmidt C, et al. Validation
 514 analyses of an operational fire monitoring product: The Hazard Mapping System. Int J
 515 Remote Sens. 2008 Oct 20;29(20):6059–66.
- 516 32. OFFICE OF POLICY DEVELOPMENT AND RESEARCH (PD&R). HUD USPS ZIP
- 517 CODE CROSSWALK FILES [Internet]. U.S. Department of Housing and Urban
- 518 Development; [cited 2021 Nov 12]. Available from:
- 519 https://www.huduser.gov/portal/datasets/usps_crosswalk.html#data
- 33. Wilson, Ron, Din, Alexander. Understanding and Enhancing the U.S. Department of
 Housing and Urban Development's ZIP Code Crosswalk Files. Cityscape J Policy Dev Res.
 2018;20(2):277–94.
- 523 34. Snowden JM, Bovbjerg ML, Dissanayake M, Basso O. The curse of the perinatal
 524 epidemiologist: inferring causation amidst selection. Curr Epidemiol Rep. 2018
 525 Dec;5(4):379–87.
- 35. Willson BE, Gee NA, Willits NH, Li L, Zhang Q, Pinkerton KE, et al. Effects of the 2018
 Camp Fire on birth outcomes in non-human primates: Case-control study. Reprod Toxicol.
 2021 Oct 1;105:128–35.
- 36. Bongaerts E, Nawrot TS, Van Pee T, Ameloot M, Bové H. Translocation of (ultra)fine
 particles and nanoparticles across the placenta; a systematic review on the evidence of in
 vitro, ex vivo, and in vivo studies. Part Fibre Toxicol. 2020 Nov 2;17(1):56.

37. Bongaerts E, Aengenheister L, Dugershaw BB, Manser P, Roeffaers MBJ, Ameloot M, et al.
Label-free detection of uptake, accumulation, and translocation of diesel exhaust particles in
ex vivo perfused human placenta. J Nanobiotechnology. 2021 May 17;19(1):144.

- 535 38. Engelen L. Translocation of airborne black carbon particles from mother to unborn child: an
 536 ENVIRONAGE birth cohort study. :29.
- 537 39. Chang J, Streitman D. Physiologic Adaptations to Pregnancy. Neurol Clin. 2012 Aug
 538 1;30(3):781–9.
- 539 40. Fleming S, Thompson M, Stevens R, Heneghan C, Plüddemann A, Maconochie I, et al.
 540 Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a
 541 systematic review of observational studies. Lancet. 2011 Mar 19;377(9770):1011–8.
- 542 41. Bai H, Capitanio JP, Miller LA, Clougherty JE. Social status and susceptibility to wildfire
 543 smoke among outdoor-housed female rhesus monkeys: A natural experiment. Heliyon. 2021
 544 Nov 1;7(11):e08333.
- 545 42. Schultz ES, Gruzieva O, Bellander T, Bottai M, Hallberg J, Kull I, et al. Traffic-related Air
 546 Pollution and Lung Function in Children at 8 Years of Age: A Birth Cohort Study. Am J
 547 Respir Crit Care Med. 2012 Dec 15;186(12):1286–91.
- 548 43. Jedrychowski WA, Perera FP, Spengler JD, Mroz E, Stigter L, Flak E, et al. Intrauterine
 549 exposure to fine particulate matter as a risk factor for increased susceptibility to acute
 550 broncho-pulmonary infections in early childhood. Int J Hyg Environ Health. 2013
 551 Jul;216(4):395–401.
- 44. Odo DB, Yang IA, Knibbs LD. A Systematic Review and Appraisal of Epidemiological
 Studies on Household Fuel Use and Its Health Effects Using Demographic and Health
 Surveys. Int J Environ Res Public Health. 2021 Feb 3;18(4):1411.
- 45. Karr C, Demers P, Koehoorn M. Influence of ambient air pollutant sources on clinical
 encounters for infant bronchiolitis. Am J Respir Crit Care Med. 2009;180:995–1001.
- 46. Seeni I, Ha S, Nobles C, Liu D, Sherman S, Mendola P. Air pollution exposure during
 pregnancy: maternal asthma and neonatal respiratory outcomes. Ann Epidemiol. 2018 Sep
 1;28(9):612-618.e4.
- 47. Rosa MJ, Just AC, Kloog I, Pantic I, Schnaas L, Lee A, et al. Prenatal particulate matter
 exposure and wheeze in Mexican children: Effect modification by prenatal psychosocial
 stress. Ann Allergy Asthma Immunol. 2017 Sep 1;119(3):232-237.e1.
- 48. Chiu YHM, Coull BA, Sternthal MJ, Kloog I, Schwartz J, Cohen S, et al. Effects of prenatal
 community violence and ambient air pollution on childhood wheeze in an urban population.
 J Allergy Clin Immunol. 2014 Mar 1;133(3):713-722.e4.
- 566 49. Soh SE, Goh A, Teoh OH, Godfrey KM, Gluckman PD, Shek LPC, et al. Pregnancy
 567 Trimester-Specific Exposure to Ambient Air Pollution and Child Respiratory Health

- Outcomes in the First 2 Years of Life: Effect Modification by Maternal Pre-Pregnancy BMI.
 Int J Environ Res Public Health. 2018 May;15(5):996.
- 570 50. Latzin P, Röösli M, Huss A, Kuehni CE, Frey U. Air pollution during pregnancy and lung
 571 function in newborns: a birth cohort study. Eur Respir J. 2009 Mar 1;33(3):594–603.
- 572 51. Jedrychowski WA, Perera FP, Maugeri U, Mroz E, Klimaszewska-Rembiasz M, Flak E, et
 573 al. Effect of prenatal exposure to fine particulate matter on ventilatory lung function of
 574 preschool children of non-smoking mothers. Paediatr Perinat Epidemiol. 2010;24(5):492–
 575 501.
- 576 52. Land SC, Wilson SM. Redox Regulation of Lung Development and Perinatal Lung
 577 Epithelial Function. Antioxid Redox Signal. 2005 Jan;7(1–2):92–107.
- 578 53. Kajekar R. Environmental factors and developmental outcomes in the lung. Pharmacol Ther.
 579 2007 May 1;114(2):129–45.
- 580 54. Korten I, Ramsey K, Latzin P. Air pollution during pregnancy and lung development in the
 child. Paediatr Respir Rev. 2017 Jan 1;21:38–46.
- 55. Dugershaw BB, Aengenheister L, Hansen SSK, Hougaard KS, Buerki-Thurnherr T. Recent
 insights on indirect mechanisms in developmental toxicity of nanomaterials. Part Fibre
 Toxicol. 2020 Jul 11;17(1):31.
- 585 56. Veras MM, de Oliveira Alves N, Fajersztajn L, Saldiva P. Before the first breath: prenatal
 exposures to air pollution and lung development. Cell Tissue Res. 2017 Mar 1;367(3):445–
 55.
- 57. Brown AP, Cai L, Laufer BI, Miller LA, LaSalle JM, Ji H. Long-term effects of wildfire
 smoke exposure during early life on the nasal epigenome in rhesus macaques. Environ Int.
 2022 Jan 1;158:106993.
- 58. O' Lenick CR, Chang HH, Kramer MR, Winquist A, Mulholland JA, Friberg MD, et al.
 Ozone and childhood respiratory disease in three US cities: evaluation of effect measure
 modification by neighborhood socioeconomic status using a Bayesian hierarchical approach.
 Environ Health. 2017 Apr 5;16(1):36.
- 595 59. Chen L, Bell EM, Caton AR, Druschel CM, Lin S. Residential mobility during pregnancy
 596 and the potential for ambient air pollution exposure misclassification. Environ Res. 2010 Feb
 597 1;110(2):162–8.
- 60. Pennington AF, Strickland MJ, Klein M, Zhai X, Russell AG, Hansen C, et al. Measurement
 error in mobile source air pollution exposure estimates due to residential mobility during
 pregnancy. J Expo Sci Environ Epidemiol. 2017 Sep;27(5):513–20.
- 601 61. Carey MA, Card JW, Voltz JW, Arbes SJ, Germolec DR, Korach KS, et al. It's all about sex:
 602 gender, lung development and lung disease. Trends Endocrinol Metab. 2007 Oct
 603 1;18(8):308–13.

- 604 62. Minghetti L, Greco A, Zanardo V, Suppiej A. Early-life sex-dependent vulnerability to
- 605 oxidative stress: the natural twining model. J Matern Fetal Neonatal Med. 2013
 606 Feb;26(3):259–62.

Tables

 Table 1. Cohort composition in the full cohort and the gestational age sub-cohort, overall and by sex.

 Full cohort

	<u>Full cohort</u>			Gestational age sub-cohort		
						FEMALE
	ALL CHILDREN	MALE CHILDREN	FEMALE CHILDREN	ALL CHILDREN	MALE CHILDREN	CHILDREN
	(N = 182,387)	(N=93,321)	(N = 89,066)	(N = 113,154)	(N=57,682)	(N=55,472)
Birth Season						
Spring	50,733 (27.8%)	26,128 (28.0%)	24,605 (27.6%)	32,269 (28.5%)	16,546 (28.7%)	15,723 (28.3%)
Summer	50,290 (27.6%)	25,801 (27.6%)	24,489 (27.5%)	31,858 (28.2%)	16,345 (28.4%)	15,513 (28.0%)
Fall	44,777 (24.6%)	22,708 (24.3%)	22,069 (24.8%)	26,338 (23.3%)	13,294 (23.1%)	13,044 (23.5%)
Winter	36,587 (20.1%)	18,684 (20.0%)	17,903 (20.1%)	22,689 (20.1%)	11,497 (20.0%)	11,192 (20.2%)
Birth Year						
2010	25,031 (13.7%)	12,513 (13.4%)	12,518 (14.1%)	15,391 (13.6%)	7,614 (13.2%)	7,777 (14.0%)
2011	27,143 (14.9%)	13,841 (14.8%)	13,302 (14.9%)	18,203 (16.1%)	9,225 (16.0%)	8,978 (16.2%)
2012	32,721 (17.9%)	16,736 (17.9%)	15,985 (17.9%)	23,127 (20.4%)	11,780 (20.5%)	11,347 (20.5%)
2013	32,438 (17.8%)	16,686 (17.9%)	15,752 (17.7%)	23,343 (20.6%)	11,924 (20.7%)	11,419 (20.6%)
2014	27,543 (15.1%)	14,196 (15.2%)	13,347 (15.0%)	21,279 (18.8%)	11,003 (19.1%)	10,276 (18.5%)
2015	18,933 (10.4%)	9,833 (10.5%)	9,100 (10.2%)	11,811 (10.4%)	6,136 (10.7%)	5,675 (10.2%)
2016	18,578 (10.2%)	9,516 (10.2%)	9,062 (10.2%)	-	-	-
Gestational Age						
less than 28 wks	449 (0.2%)	237 (0.3%)	212 (0.2%)	449 (0.4%)	237 (0.4%)	212 (0.4%)
28 to 36 wks	8,433 (4.6%)	4,396 (4.7%)	4,037 (4.5%)	8,433 (7.5%)	4,396 (7.6%)	4,037 (7.3%)
greater than 36						
wks	104,216 (57.1%)	53,049 (56.8%)	51,223 (57.5%)	104,216 (92.1%)	53,049 (92.1%)	51,223 (92.3%)
missing	69,289 (38%)	35,639 (38.2%)	33,594 (37.7%)	-	-	-
Upper respiratory me	edication claim					
No	179,939 (98.7%)	91,935 (98.5%)	88,004 (98.8%)	111,752 (98.8%)	56,880 (98.8%)	54,872 (98.9%)
Yes	2,448 (1.3%)	1,386 (1.5%)	1,062 (1.2%)	1,402 (1.2%)	802 (1.4%)	600 (1.1%)
Lower respiratory me	edication claim					
No	148,646 (81.5%)	73,668 (78.9%)	74,978 (84.2%)	92,707 (81.9%)	45,810 (79.6%)	46,897 (84.5%)
Yes	33,741 (18.5%)	19,653 (21.1%)	14,088 (15.8%)	20,447 (18.1%)	11,872 (20.6%)	8,575 (15.5%)
Systemic anti-inflam	matory medication cla	im				
No	158,348 (86.8%)	79,068 (84.7%)	79,280 (89.0%)	98,549 (87.1%)	49,048 (85.2%)	49,501 (89.2%)
Yes	24,039 (13.2%)	14,253 (15.3%)	9,786 (11%)	14,605 (12.9%)	8,634 (15%)	5,971 (10.8%)

Table 2. Mixed effects cox model of smoke exposure during post-partum trimester at the 25% exposure threshold, in all eligible children and stratified by sex. P1 and P2 periods correspond to 0-12 and 13-24 weeks, respectively. Models are adjusted for birth-season, birthyear and, where applicable, sex, with a random intercept for MSA. All exposures are the average weekly number of smoke-days in the given post-partum period. RX = prescribed medication claim.

		ALL CHILDREN	MALE CHILDREN	FEMALE CHILDREN
		(N = 182,387)	(N = 93,321)	(N = 89,066)
	Exposur			
	е	HR (95% CI)	HR (95% CI)	HR (95% CI)
Upper respiratory DV	P1	1.094 (1.005, 1.191)	1.055 (0.940, 1.185)	1.123 (0.994, 1.270)
Opper respiratory KX	P2	1.108 (1.016, 1.209)	1.128 (1.004, 1.266)	1.072 (0.942, 1.220)
Lowon nooningtony DV	P1	1.007 (0.983, 1.031)	1.013 (0.982, 1.045)	0.992 (0.955, 1.030)
Lower respiratory KA	P2	0.980 (0.955, 1.007)	0.971 (0.938, 1.005)	0.987 (0.947, 1.029)
Systemic Anti-	P1	1.001 (0.975, 1.028)	0.995 (0.961, 1.030)	1.008 (0.966, 1.051)
inflammatory RX	P2	0.996 (0.969, 1.025)	1.004 (0.968, 1.042)	0.980 (0.938, 1.025)

Table 3. Mixed effects cox model results of smoke exposure during gestational periods at the 25% exposure threshold, in all eligible children and stratified by sex. Models are adjusted for birth season, birthyear and, where applicable, sex, with a random intercept for MSA. The first and second N values correspond to the entire cohort (full cohort) and the cohort portion whose gestational age estimate was available to estimate wildfire smoke-day exposure (GA sub-cohort), respectively. All exposures are the average weekly number of smoke-days in the given period. RX = prescribed medication claim.

			ALL CHILDREN	MALE CHILDREN		
			(N = 182,387 /	(N = 93,321 /	FEMALE CHILDREN	
			113,154)	57,682)	(N = 89,066 / 55,472)	
		Exposur				
Outcome	Cohort	е	HR (95% Cl)	HR (95% CI)	HR (95% Cl)	
Upper respiratory RX	Full cohort					
		T1	1.082 (0.985, 1.188)	1.026 (0.902, 1.167)	1.140 (0.997, 1.303)	
		T2	0.978 (0.876, 1.093)	1.079 (0.935, 1.245)	0.857 (0.722, 1.018)	
		Т3	0.913 (0.821, 1.014)	0.884 (0.766, 1.020)	0.948 (0.812, 1.107)	
	GA sub-					
Upper respiratory RX	cohort					
		T1	1.094 (0.974, 1.229)	1.066 (0.910, 1.249)	1.121 (0.949, 1.324)	
		Т2	0.935 (0.806, 1.085)	0.978 (0.806, 1.186)	0.882 (0.701, 1.108)	
		Т3	0.948 (0.833, 1.080)	0.957 (0.804, 1.140)	0.931 (0.770, 1.127)	
Lower respiratory RX	Full cohort					
		T1	0.977 (0.951, 1.003)	0.960 (0.927, 0.993)	0.997 (0.956, 1.039)	
		T2	0.986 (0.957, 1.017)	0.987 (0.949, 1.027)	0.978 (0.933, 1.026)	
		Т3	0.992 (0.966, 1.019)	1.004 (0.969, 1.040)	0.970 (0.930, 1.012)	
	GA sub-					
Lower respiratory RX	cohort					
		T1	0.966 (0.935, 0.999)	0.959 (0.918, 1.002)	0.969 (0.920, 1.021)	
		Т2	0.968 (0.930, 1.008)	0.966 (0.917, 1.018)	0.962 (0.903, 1.025)	
		Т3	0.972(0.939, 1.005)	0.982 (0.940, 1.027)	0.948 (0.899, 1.000)	
Systemic Anti-inflam.						
RX	Full cohort					
		T1	0.976 (0.948, 1.005)	0.978 (0.941, 1.016)	0.973 (0.929, 1.018)	
		T2	0.968 (0.935, 1.001)	0.967 (0.925, 1.010)	0.967 (0.916, 1.020)	
		Т3	0.996 (0.966, 1.027)	1.008 (0.968, 1.049)	0.975 (0.930, 1.022)	
Systemic Anti-inflam.	GA sub-					
RX	cohort					
		T1	0.962 (0.927, 0.997)	0.959 (0.914, 1.006)	0.963 (0.910, 1.019)	
		T2	0.946 (0.905, 0.989)	0.921 (0.869, 0.976)	0.982 (0.917, 1.053)	
		Т3	0.989 (0.953, 1.027)	1.024 (0.975, 1.075)	0.935 (0.882, 0.992)	

Figure Captions

Figure 1. Cohort construction. WA, OR, CA, MT, NV, and ID refer to the states of Washington, Oregon, California, Montana, Nevada, and Idaho, respectively. MSA is Metropolitan Statistical Area and CONUS is Continental United States.

Figure 2. Spatial distribution of total number of smoke-days (2010-2016) at each MSA for the (a) 0%, (b) 25%, and (c) 50% thresholds. Thresholds are defined as the population-weighted percentage of zip codes within an MSA required to experience a smoke-day, in order to assign a smoke-day to the MSA.

Figure 3. Hazard ratio and confidence intervals for the relationship of average weekly smoke-days and first use of prescription outcome, in each averaging period at the 25% exposure threshold, for all children (green square), and within strata of male children (purple diamonds) and female children (orange circle). The Cox proportional hazards models were adjusted for birth season, birth year, infant sex and included a random intercept for metropolitan statistical area; infant sex covariate was omitted in infant sex-stratified models. rx = prescribed medication claim; T1-T3 refer to the first-third trimesters; P1 and P2 refer to the first and second 12-week post-natal period.

2,088,936 live births with estimable birthdates in CONUS (2010-16)

237,003 born into MSAs in the study region

184,703 with prescription coverage

184,703 with complete smoke density day exposure estimates

113,154 with gestational age 1,851,933 in states outside of WA, OR, CA, MT,NV, & ID

52,300 without prescription coverage

71,549 without gestational age







